Prototype Quantitative Assay for Fibrinogen/Fibrin Degradation Products: Clinical Evaluation

Samuel Harold Sigal, George S. Cembrowski, Sanford J. Shattil, Nancy M. Brown, Richard S. Schifreen, Mark W. Schwartz

Research output: Contribution to journalArticlepeer-review


A new quantitative assay for fibrinogen/fibrin degradation products (FDPs) was clinically evaluated in 123 tertiary-care patients for whom the standard semiquantitative FDP assay had previously been ordered. On the basis of a comprehensive chart review, 24 patients were categorized as having disseminated intravascular coagulation (DIC), 84 were considered not to have had DIC, ten had fibrinolysis (nine of ten streptokinase induced), and five had a complicated coagulopathy whose exact nature could not be determined. The quantitative and semiquantitative FDP values were significantly correlated. However, the FDP level indicative of DIC was lower by the quantitative assay than by the semiquantitative assay, approximately 18 mg/L vs 40 mg/L, respectively. The advantages of the quantitative over the semiquantitative assay included improved precision and ability to closely monitor changes in the severity of the coagulopathy.

Original languageEnglish (US)
Pages (from-to)1790-1793
Number of pages4
JournalArchives of internal medicine
Issue number10
StatePublished - Oct 1987
Externally publishedYes

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Prototype Quantitative Assay for Fibrinogen/Fibrin Degradation Products: Clinical Evaluation'. Together they form a unique fingerprint.

Cite this